Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States. It develops Lpathomab, a humanized monoclonal antibody (mAb) against lysophosphatidic acid that has completed Phase 1a clinical trial for various chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain, and pain associated with lumbosacral radiculopathy. The company also develops iSONEP, a mAb against sphingosine-1-phosphate, which is in Phase II clinical trial for the treatment of wet age-related macular degeneration; and ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid sphingosine-1-phosphate (S1P), which is in Phase IIa clinical trial to treat kidney cancer, leukemia, prostate cancer, neuroblastoma, lung cancer, pancreatic cancer, and melanoma. Lpath, Inc. has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.

Apollo Endosurgery Inc

Apollo Endosurgery, Inc. develops medical devices. It offers medical devices for bariatric and gastrointestinal procedures. The firm's brands include Orbera, Lap-band SYSTEM and OverStitch. The company was founded by Christopher J. Gostout in 2006 and is headquartered in Austin, TX.

Should you buy, sell, or hold Apollo Endosurgery Inc (APEN) ?

Apollo Endosurgery Inc (APEN) : Buy or Sell